Krystal Biotech, Inc. (KRYS)
| Market Cap | 9.85B +126.5% |
| Revenue (ttm) | 440.48M +22.6% |
| Net Income | 241.46M +64.6% |
| EPS | 7.97 +62.4% |
| Shares Out | 29.60M |
| PE Ratio | 41.78 |
| Forward PE | 39.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 148,465 |
| Open | 332.18 |
| Previous Close | 335.73 |
| Day's Range | 330.31 - 337.41 |
| 52-Week Range | 136.73 - 382.54 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 382.86 (+15.04%) |
| Earnings Date | Aug 3, 2026 |
About KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey... [Read more]
Financial Performance
In 2025, Krystal Biotech's revenue was $389.13 million, an increase of 33.94% compared to the previous year's $290.52 million. Earnings were $204.83 million, an increase of 129.74%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price target is $382.86, which is an increase of 15.04% from the latest price.
News
Krystal Biotech Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue growth, strong U.S. and international demand for VYJUVEK, and progress in clinical and regulatory milestones. Net revenue rose 24% year-over-year, with over 730 U.S. reimbursement approvals and continued global expansion.
Krystal Biotech Earnings release: Q2 2026
Krystal Biotech released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Krystal Biotech Quarterly report: Q2 2026
Krystal Biotech has published its Q2 2026 quarterly earnings report on August 3, 2026.
Krystal Biotech Slides: Q2 2026
Krystal Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance s...
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 20...
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Krystal Biotech Slides: Corporate presentation
Krystal Biotech has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic...
Krystal Biotech Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and compensation approvals, with all proposals passing. A brief Q&A followed the formal business, and final voting results will be filed with the SEC.
Krystal Biotech Transcript: Bank of America Global Healthcare Conference 2026
Strong financial performance continues with high gross margins and expanding global launches, particularly in Europe and Japan. Pipeline progress includes fully enrolled ocular DEB and neurotrophic keratitis studies, and a cystic fibrosis program advancing toward pivotal trials.
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference o...
Krystal Biotech Earnings Call Transcript: Q1 2026
Q1 2026 saw 32% year-over-year revenue growth to $116.4M, with strong VYJUVEK performance in the U.S., Europe, and Japan, 95% gross margin, and net income of $55.9M. Six clinical data readouts, including two registrational studies, are expected before year-end.
Krystal Biotech Earnings release: Q1 2026
Krystal Biotech released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Krystal Biotech Quarterly report: Q1 2026
Krystal Biotech has published its Q1 2026 quarterly earnings report on May 4, 2026.
Krystal Biotech Slides: Q1 2026
Krystal Biotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) regi...
Krystal Biotech to Present at Upcoming Scientific Conferences
PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conf...
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026,...
Krystal Biotech Proxy statement: Proxy filing
Krystal Biotech filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Krystal Biotech Proxy statement: Proxy filing
Krystal Biotech filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Krystal Biotech Slides: Corporate presentation
Krystal Biotech has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Krystal Biotech Transcript: TD Cowen 46th Annual Health Care Conference
VYJUVEK's Q4 growth was driven by U.S. sales force expansion and a label update for at-home dosing, with ROW sales expected to lead 2026 growth. Pipeline programs in ocular and NK are advancing pivotal trials with increased dosing frequency, and the CF program is progressing through positive FDA discussions.
Krystal Biotech Earnings Call Transcript: Q4 2025
VYJUVEK delivered strong revenue growth in Q4 and 2025, driven by U.S. and accelerating ex-U.S. launches, with gross margins at 94% and robust net income. Pipeline progress, global expansion, and new FDA designations position the company for continued growth in 2026.